News

Omadacycline (Nuzyra) maintained its potency over time and did not show a decrease in effectiveness.

A Spanish man contracted the virus after a tick bite and succumbed to it last week.

HepB-BD is unavailable in 17 countries, and the number of young children receiving the HepB3 shot has dropped by 10 percentage points or more.

A bill in the House of Representatives was just introduced with the advocacy of the Peggy Lillis Foundation in hopes of bringing more recognition and research to the healthcare-associated infection.

A hospital CDI intervention program that supported patients via an ID specialist demonstrated clinical benefits compared to another hospital where patients were followed by providers of any specialty.

New study reveals a marked reduction in HCV infection rates, falling from 23.4% in 2017 to 6% in 2023.

New funding will go towards research around a specific molecule that has been shown to lower inflammation.

Malaria control efforts can be impacted by indoor nuisance pest management as ineffective control of pests may erode community trust in vector control products.

A new study looks at the role of genetics in the leveling degrees of infection.

A secondary analysis of a randomized trial points to limited benefits on the microbiota.

Boar’s Head is recalling its liverwurst product as well as other deli meats due to concerns around contamination.

Merck’s antibody, clesrovimab (MK-1654), is designed to protect infants against medically attended lower respiratory infections (MALRI) caused by RSV.

This week, NYC has revealed high rates of Hepatitis C virus reinfection, SHEA tackles antimicrobial resistance amidst challenges during the COVID-19 pandemic, and more this week from Contagion.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

Multimonth dispensing recipients show a notable decrease in discontinuation rates, highlighting its potential to improve long-term treatment adherence and retention in HIV care programs.

The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.

Three studies provide insights into the ongoing COVID-19 pandemic, the prevalence of post-COVID conditions among primary care patients, the effectiveness of nirmatrelvir/ritonavir treatment, and declines in primary care visits.

SHEA supports funding to address antimicrobial resistance in light of heightened challenges during the COVID-19 pandemic.

The largest head-to-head randomized clinical trial confirms results and also shows the 2-therapy regimen led to less weight gain.

While the SCORPIO-HR phase 3 trial did not meet its primary endpoint of sustained symptom resolution, ensitrelvir showed promising results in reducing symptom duration and preventing viral rebound.

A pilot study looked at offering this form of pre-exposure prophylaxis (PrEP) to a select population to see if it could be effective in preventing sexually transmitted infections (STIs).

Despite advances in antiviral treatments, the study reveals that traditional prevention strategies have not curbed reinfection rates among men who have sex with men linked to specific high-risk behaviors.

Paratek Pharmaceuticals has announced results from a Phase 3 study of omadacycline (Nuzyra), demonstrating its non-inferiority to moxifloxacin in treating moderate to severe community-acquired bacterial pneumonia.

This upcoming Sunday, July 28, is this year’s World Hepatitis Day and it is an opportunity to raise awareness, deliver education to the masses, and continue to support the research and treatments to reduce the incidence rates of the infection.

Participants using nasal sprays experienced significantly shorter illness durations and reduced antibiotic usage compared to those receiving usual care.

A study finds clinically-relevant sub-phenotypes can be reproducibly, and could lead to patient stratification and treatment.

Evaluating nirmatrelvir–ritonavir over 5-10 days for post-exposure prophylaxis revealed no reduction in symptomatic SARS-CoV-2 infections compared to placebo among asymptomatic adults.

CDC reports 2 deaths so far, and several more people sickened across multiple states.